Get started
Author

Miguel Beltrán

Observed names: Beltrán-Sánchez, Miguel Ángel, M. Beltran, M. Beltrán, M.Á. Beltrán, Miguel Angel Beltran, Miguel Angel Beltran Sanchez, Miguel Angel Beltrán, Miguel Beltran
Observed institutions: Universitat de València, Hospital Universitario La Paz, Hospital de Sant Pau, Hospital Universitari Arnau de Vilanova, Hospital Clínico San Carlos, Hospital Universitari i Politècnic La Fe, Hospital Son Llatzer, Hospital General Universitario Morales Meseguer, Althaia, Hospital Universitari Sant Joan D'Alacant, Complejo Hospitalario Universitario de Santiago, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Consorci Sanitari de Terrassa, Hospital Universitario Fundación Alcorcón, Institut Català d'Oncologia, Hospital Virgen de la Salud, Hospital Universitario Miguel Servet, Hospital General Universitario de Elche, Hospital Arnau de Vilanova, Hospital Santa Caterina, Hospital General Universitario De Valencia, Hospital Universitario Son Dureta, Hospital Universitario Central de Asturias, Hospital de Mataró, Donostiako Unibertsitate Ospitalea, Fundación Hospital Provincial de Castellón, Hospital General de Elda, Hospital Universitario Virgen de la Arrixaca, Hospital Universitari de Girona Doctor Josep Trueta, INCLIVA Health Research Institute, Hospital Universitario de Jerez
ORCID: 0000-0001-9450-2973
Observed ORCID: 0000-0001-9450-2973
OpenAlex ID: A5077544693
Green gentrification in European and North American cities
2022 · Isabelle Anguelovski, James J. T. Connolly, et al. · Nature Communications · 502
PDF
Exploring green gentrification in 28 global North cities: the role of urban parks and other types of greenspaces
2022 · Margarita Triguero-Mas, Isabelle Anguelovski, et al. · Environmental Research Letters · 71
PDF
Comparative effectiveness of contact tracing interventions in the context of the COVID-19 pandemic: a systematic review
2023 · Francisco Pozo-Martin, Miguel Angel Beltran Sanchez, et al. · European Journal of Epidemiology · 47
PDF
Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial
1985 · Pablo Viladiu, Maria Carmen Alonso, et al. · Cancer · 27
PDF
Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis
1998 · X. Garcia-del-Muro, C. Vadell, et al. · European Journal of Cancer · 19
Validation of the 2001 St Gallen Risk Categories for Node-Negative Breast Cancer Using a Database From the Spanish Breast Cancer Research Group (GEICAM)
2004 · R. Colomer, G. Viñas, et al. · Journal of Clinical Oncology · 17
Does greening generate exclusive residential real estate development? Contrasting experiences from North America and Europe
2024 · Isabelle Anguelovski, Emilia Oscilowicz, et al. · Urban forestry & urban greening · 16
CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
2010 · Ana Oaknin, Pilar Barretina, et al. · International Journal of Gynecological Cancer · 10
Alternating sequential endocrine therapy: Tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients
1991 · M. Beltrán, M.C. Alonso, et al. · Annals of Oncology · 5
PDF
Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.
2011 · C. Suarez, E. Gallardo, et al. · Journal of Clinical Oncology · 4
Neurological assessment of high grade astrocytomas following high dose radiotherapy as sole treatment
1995 · R. Fuentes, A.X. Izquierdo, et al. · Clinical Oncology · 4
A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.
2021 · Anna Adam-Artigues, Miguel Angel Beltran, et al. · Journal of Clinical Oncology · 2
Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).
2016 · Ignacio Matos, Juan J. Grau, et al. · Journal of Clinical Oncology · 2
Abiraterone after docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients (p) in an off-protocol routine clinical setting.
2014 · Maria Ochoa de Olza, Albert Font, et al. · Journal of Clinical Oncology · 2
Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients.
2011 · B. Ojeda, A. Casado, et al. · Journal of Clinical Oncology · 2
Prognostic index for safety and compliance of docetaxel/ciplatin/5-fluorouracil (TPF) induction followed by radiochemotherapy (RT-CT) in 203 patients (pts) with unresectable squamous cell carcinoma of the head and neck (USCCHN).
2010 · F. Peyrade, C. Mercier, et al. · Journal of Clinical Oncology · 2
Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).
2014 · Jaume Capdevila, Javier Martinez-Trufero, et al. · Journal of Clinical Oncology · 1
Second primary gynecologic neoplasms among breast cancer survivors.
2012 · Maria Pilar Barretina Ginesta, Miguel Beltran, et al. · Journal of Clinical Oncology · 1
Precomputed posterior samples for "A multivariate spatial model for ordinal survey-based data"
2026 · Beltrán-Sánchez, Miguel Ángel, Martínez-Beneito, Miguel Ángel, et al. · Zenodo (CERN European Organization for Nuclear Research)
195P A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients
2021 · A. Adam Artigues, M.Á. Beltrán, et al. · Annals of Oncology
Safety and Efficacy of Vandetanib As Systemic Treatment for Patients with Advanced and Progressive Medullary Thyroid Cancer (Mtc)
2014 · E. Grande, J. Martinez-Trufero, et al. · Annals of Oncology
Clinical experience with oral vinorelbine (NVBO) plus prednisone as first- or second-line chemotherapy of metastatic hormone-refractory prostate cancer (HRPC).
2012 · Jose Manuel Cervera Grau, Miguel Beltran, et al. · Journal of Clinical Oncology
Clinical experience with oral vinorelbine (NVB) plus prednisone as first- or second-line chemotherapy of metastatic hormone- refractory prostate cancer (HRPC)
2009 · J. M. Cervera, I. Garcia-Carbonero, et al. · Journal of Clinical Oncology
Residual tumor status in clinical trials of advanced ovarian cancer: A systematic review
2006 · M. Beltrán, X. Hernández, et al. · Journal of Clinical Oncology
P101 Randomized trial of two versus four years of adjuvant tamoxifen (AT) for postmenopausal women with node positive breast cancer
1998 · M. Gallén, C. Alonso, et al. · European Journal of Cancer
Works count: 28
Citation count: 734
H-index: 8
I10-index: 8
Year
Topic
Type